Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kluft

Showing results (91-100 of 291) with videos related to

Pageof 30
Sort By:
Annals of the New York Academy of Sciences|December 4, 1992
Platelet-derived growth factor increases plasminogen activator inhibitor-1 activity and mRNA in rat cultured vascular smooth muscleG Sperti, R van Leeuwen, A Maseri, et al.
Thrombosis and Haemostasis|March 1, 1995
On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasmaL G Huisman, J M van Griensven, C Kluft
Clinical Chemistry|January 1, 1994
Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluatedP Meijer, D E Pollet, J Wauters, et al.
Blood|June 1, 1982
A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasminC Kluft, E Vellenga, E J Brommer, et al.
Acta Haematologica|January 1, 1983
Acute lymphocytic leukaemia complicated by hypofibrinogenaemia without evidence for impaired fibrinogen synthesis or disseminated intravascular coagulationE Vellenga, G W van Imhoff, L Sterrenberg, et al.
The Biochemical Journal|October 15, 1988
Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasminD C Rijken, E Groeneveld, C Kluft, et al.
Diabetes Care|October 1, 1989
Tissue plasminogen activator inhibition in diabetes mellitusM Small, C Kluft, A C MacCuish, et al.
Thrombosis and Haemostasis|December 20, 1993
Hereditary increase of plasma histidine-rich glycoprotein associated with abnormal heparin binding (HRG Eindhoven)J J Hoffmann, B C Hennis, C Kluft, et al.
Annals of the New York Academy of Sciences|December 4, 1992
Clearance of plasminogen activator--a major determinant of plasma concentration: therapeutic and diagnostic implicationsA F Cohen, K Burggraaf, A de Boer, et al.
Lancet (London, England)|January 6, 1996
World distribution of factor V Leiden mutationM P de Maat, C Kluft, J Jespersen, et al.
Pageof 30

Showing results (91-100 of 291) with videos related to

Sort By:
Pageof 30
Annals of the New York Academy of Sciences|December 4, 1992
Platelet-derived growth factor increases plasminogen activator inhibitor-1 activity and mRNA in rat cultured vascular smooth muscleG Sperti, R van Leeuwen, A Maseri, et al.
Thrombosis and Haemostasis|March 1, 1995
On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasmaL G Huisman, J M van Griensven, C Kluft
Clinical Chemistry|January 1, 1994
Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluatedP Meijer, D E Pollet, J Wauters, et al.
Blood|June 1, 1982
A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasminC Kluft, E Vellenga, E J Brommer, et al.
Acta Haematologica|January 1, 1983
Acute lymphocytic leukaemia complicated by hypofibrinogenaemia without evidence for impaired fibrinogen synthesis or disseminated intravascular coagulationE Vellenga, G W van Imhoff, L Sterrenberg, et al.
The Biochemical Journal|October 15, 1988
Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasminD C Rijken, E Groeneveld, C Kluft, et al.
Diabetes Care|October 1, 1989
Tissue plasminogen activator inhibition in diabetes mellitusM Small, C Kluft, A C MacCuish, et al.
Thrombosis and Haemostasis|December 20, 1993
Hereditary increase of plasma histidine-rich glycoprotein associated with abnormal heparin binding (HRG Eindhoven)J J Hoffmann, B C Hennis, C Kluft, et al.
Annals of the New York Academy of Sciences|December 4, 1992
Clearance of plasminogen activator--a major determinant of plasma concentration: therapeutic and diagnostic implicationsA F Cohen, K Burggraaf, A de Boer, et al.
Lancet (London, England)|January 6, 1996
World distribution of factor V Leiden mutationM P de Maat, C Kluft, J Jespersen, et al.
Pageof 30